Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429278 | 0.92 | SIGMAR1 (0.45) | SIGMAR1HPGDMLYCDKDM4EHSD17B10 | |
| SCHEMBL4782817 | 0.87 | HPGD (0.47) | SIGMAR1HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL19169602 | 0.86 | HPGD (0.41) | SIGMAR1HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13374400 | 0.86 | MEN1 (0.43) | SIGMAR1HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13374396 | 0.85 | MEN1 (0.46) | SIGMAR1HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL19767706 | 0.85 | HPGD (0.43) | SIGMAR1HPGDMLYCDKDM4EHSD17B10 | |
| SCHEMBL24193577 | 0.83 | MEN1 (0.45) | SIGMAR1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22664218 | 0.83 | MEN1 (0.45) | SIGMAR1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25876080 | 0.83 | MEN1 (0.45) | SIGMAR1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25475907 | 0.83 | MEN1 (0.45) | SIGMAR1HPGDKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230152316-A1 | SARS-COV2 SPIKE PROTEIN BINDING PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220396643-A1 | NOVEL CROSSLINKED ALGINIC ACID STRUCTURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-15 | — | — | US | disclosed |
| US-11472892-B2 | Reactive alginic acid derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210024659-A1 | NOVEL REACTIVE ALGINIC ACID DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20180148472-A1 | AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | FGFR2, FGF2, FGFR1 | SIGMAR1 4579/4885HPGD 4494/4885MLYCD 3408/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | SIGMAR1 4375/4885HPGD 4146/4885MLYCD 4423/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | SIGMAR1 4329/4885HPGD 4226/4885MLYCD 3547/4885 |
| US-20180148472-A1 | AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING | MRPL21, ACP1, MAX | SIGMAR1 4203/4885HPGD 3616/4885MLYCD 3063/4885 |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | SIGMAR1 4439/4885HPGD 2233/4885MLYCD 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.